Background and Aim: Although treatment with direct-acting antivirals has dramatically improved morbidity and mortality attributable to chronic hepatitis C virus infection, universal access to these medicines has been slow in the Asia-Pacific region and Russia. This study evaluated efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus infection from Asia-Pacific countries and Russia (C-CORAL). Methods: C-CORAL was a phase 3, randomized, placebo-controlled study (NCT02251990). Treatment-naive, HIV-negative, cirrhotic and non-cirrhotic participants with chronic hepatitis C genotype 1, 4, or 6 infection were randomized to elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks (immediate-treatment group) or placebo followed by deferred treatment with elbasvir/grazoprevir (deferred-treatment group). The primary efficacy outcome was sustained virologic response at 12 weeks, and the primary safety outcome was a comparison between the immediate-treatment group and placebo phase of the deferredtreatment group. Results: A total of 489 participants were randomized (immediate-treatment group, n = 366; deferred-treatment group, n = 123). Sustained virologic response at 12 weeks in the combined immediate/deferred-treatment groups was 94.4% (459/486; 95% confidence interval = 92.4-96.5%). Sustained virologic response at 12 weeks was 98.2% in participants with genotype 1b, 91.9% with genotype 1a, and 66.7% with genotype 6 infection. Similar rates of adverse events and drug-related adverse events were seen in the immediatetreatment group versus placebo phase of the deferred-treatment group (51.0% vs 50.4% and 21.4% vs 21.1%). Conclusions: Elbasvir/grazoprevir for 12 weeks represents an effective and well-tolerated treatment option for treatment-naive people with genotype 1 infection from Asia-Pacific countries and Russia.
Introduction
Worldwide, an estimated 75-100 million adults are hepatitis C virus (HCV) RNA-positive, a high proportion of whom reside in East and South-East Asia. 1 In these countries, HCV infection represents a substantial health-care burden. For example, almost 9 million Chinese adults are HCV viremic and 656 000 Taiwanese adults (4.4% of the adult population) have detectable HCV viremia. 1 The once-daily, fixed-dose combination tablet of elbasvir (EBR), an NS5A inhibitor, and grazoprevir (GZR), an NS3/4A protease inhibitor, is approved in many Western countries and in Japan for the treatment of HCV genotype (GT) 1 and 4 infection and additionally in Canada for the treatment of GT3 infection in combination with sofosbuvir.
2-4 EBR and GZR exhibit broad and potent antiviral activity in laboratory assays [5] [6] [7] [8] [9] and, in combination, have demonstrated a high barrier to resistance in vitro 6 and high efficacy in phase 2/3 clinical studies of treatment-naive and treatment-experienced participants with HCV infection. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Notably, these studies have consistently shown very high rates of SVR at 12 weeks after completion of therapy (SVR12) in HCV GT1b-infected participants. 21 The objective of the phase 3 C-CORAL trial was to evaluate the efficacy and safety of a once-daily, all-oral, fixed-dose combination of EBR/GZR for 12 weeks in participants with HCV GT1, GT4, or GT6 infections from Asia-Pacific countries and Russia. Herein, we report outcomes of the prespecified primary and secondary objectives, SVR12 and SVR24, for participants in both the immediate-treatment group (ITG) and deferred-treatment group (DTG).
Methods
Study design. C-CORAL was a phase 3, randomized, international, parallel-group, placebo-controlled, double-blind study conducted at 49 study centres in mainland China (13) , Australia (2), Republic of Korea (6) , Taiwan (7), Thailand (3), Vietnam (3), and Russia (15) . An interim analysis was performed when all participants in the ITG in countries outside China, who were enrolled first due to an anticipated delay in acquiring regulatory approval in China, reached follow-up week (FW) 12. 22 The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Independent institutional review boards or ethics committees reviewed and approved the protocol and applicable amendments for each institution, and all participants gave written informed consent.
Eligible participants were randomized 3:1 to immediate or deferred treatment. Participants randomized to the ITG received the fixed-dose combination of EBR 50 mg/GZR 100 mg once daily for 12 weeks, followed by 24 weeks of follow-up. Participants randomized to the DTG received matched placebo once daily for 12 weeks, followed by 4 weeks of blinded follow-up and then 12 weeks of open-label treatment with EBR 50 mg/GZR 100 mg followed by 24 weeks of follow-up.
Study participants. Treatment-naive, cirrhotic and noncirrhotic adults aged > 18 years with chronic HCV GT1, GT4, or GT6 infection and baseline HCV RNA ≥ 10 000 IU/mL were enrolled. The presence of cirrhosis was defined as METAVIR F4 on liver biopsy within 24 months of enrollment, FibroScan ® > 12.5 kPa within 12 months of enrollment, or a combination of FibroTest ® score > 0.75 and aspartate aminotransferase (AST): platelet ratio index > 2. Key exclusion criteria were evidence of decompensated liver disease; co-infection with hepatitis B virus (defined as being HBsAg positive) or HIV; clinically relevant drug or alcohol abuse; hepatocellular carcinoma; uncontrolled diabetes (hemoglobin A1c > 10%); liver aminotransferase levels > 10× the upper limit of normal (ULN); albumin < 3.0 g/dL; elevated prothrombin time unrelated to anticoagulation; creatinine clearance < 50 mL/min; hemoglobin level < 9.5 g/dL; and platelet count < 50 × 10 3 cells/μL.
Randomization and masking. Randomization was performed centrally using an interactive voice response system/integrated web response system and was stratified according to presence or absence of cirrhosis and country of enrollment. Participants, investigators, and the sponsor were blinded to treatment assignment and HCV RNA results through week 16, after which the assignments were unmasked and participants who were randomized to the DTG received active treatment. EBR, GZR, and placebo were manufactured to preserve masking (confirmed as visually identical) and packaged identically.
Outcomes. The primary efficacy outcome variable was SVR12, defined as the proportion of participants in the ITG with undetectable HCV RNA 12 weeks after the end of treatment. Virologic failure was defined as non-response (detectable HCV RNA at end of treatment with HCV RNA greater than the lower limit of quantification [LLoQ] throughout treatment), rebound (> 1 log 10 increase in HCV RNA from nadir while on treatment), breakthrough (HCV RNA > LLoQ after previously being < LLoQ while on treatment), or relapse (HCV RNA > LLoQ during follow-up after having undetectable HCV RNA at end of treatment). The primary safety outcome was a comparison of safety between the two treatment arms during the 12-week blinded period and up to 14 days after un-blinding. Safety was assessed by monitoring adverse events (AEs), vital signs, and laboratory test results from the start of treatment through to 14 days after completion of the final dose. Late elevations in ALT or AST were defined as ALT/AST elevations > 5× ULN in participants who had ALT/AST ≤ ULN between weeks 2 and 4. Emergence of viral critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. The corresponding author had full access to the data and final responsibility for the decision to submit for publication. Financial support: The trial was sponsored and funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, which was responsible for the study design, study management, data collection, and data analysis and was involved in the writing of the report.
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Procedures. Plasma HCV RNA levels were measured by the COBAS ® AmpliPrep/COBAS ® TaqMan ® HCV test, version 2.0 (Roche Molecular Diagnostics, Branchburg, NJ, USA) with an LLoQ of 15 IU/mL and a lower limit of detection of 15 IU/mL. Specimens for viral load measurements were collected at screening, at baseline, and at regular intervals during treatment and follow-up. HCV genotype was determined using Abbott HCV Real Time Genotype II assay (Abbott Diagnostics, Chicago, IL, USA), with the genotypes of all participants from outside China also confirmed via NS5B amplicon sequence analysis. Blood samples for viral resistance-associated substitution (RAS) detection were collected at baseline and at the time of virologic failure from all participants (see Supporting Information, Detection of Viral RASs).
Statistical analysis. The target enrollment for the AsiaPacific region (including China) and Russia was 453 participants, with an interim analysis of the ITG from the ex-China cohort prespecified in the protocol. The sample size for the entire study, including the ex-China cohort, was determined by assuming a true response rate of at least 85.5% and, with at least 99.9% power to show superiority to a historical reference rate of 73% at a onesided 1.25% alpha-level, yielded a sample size of 340 in the ITG. The historical reference rate of 73% was based on data from studies of peginterferon/ribavirin in GT1-infected individuals from Taiwan and Republic of Korea, adjusted with a 5% decrease to correct for the expected improved safety profile with an interferon-free regimen and shorter treatment duration. 23, 24 The primary efficacy analysis was performed in the full analysis set population, which included all randomized participants who received at least one dose of study treatment. A two-sided 95% asymptotic confidence interval (CI) was calculated for SVR12 in the ITG. Safety analyses were conducted in all participants who received at least one dose of study medication. Resistance analyses were conducted in the resistance analysis population, which included all participants who achieved SVR12 or met criteria for virologic failure.
The study is registered at ClinicalTrials.gov (NCT02251990), and the study protocol (Protocol PN-5172-067) is available in the Supporting Information.
Results
Disposition and baseline characteristics. A total of 551 participants were screened, of whom 489 were randomized and 62 were not enrolled (Fig. 1) . Of the 62 participants who failed screening, 55 failed to meet inclusion/exclusion criteria, six withdrew before randomization, and one was withdrawn by his or her physician. The first participant received his or her first dose of study drug on March 2, 2015, and the final participant completed treatment on September 27, 2016. † Six participants in the ITG and four participants in the DTG discontinued treatment early but returned for the FW24 clinic assessment. ‡ Participant had spontaneous viral clearance but returned for the FW24 clinic assessment. AE, adverse event; DTG, deferred-treatment group; EBR, elbasvir; FW, follow-up week; GZR, grazoprevir; ITG, immediate-treatment group.
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L Wei et al. Of the 365 participants randomized to the ITG who received ≥ 1 dose of study medication, 358 (98.1%) completed 12 weeks of treatment with EBR/GZR and seven discontinued (AE, n = 1; virologic failure, n = 5; participant withdrawal, n = 1). Of the 123 participants randomized to the DTG, 122 completed 12 weeks of treatment with placebo (one participant discontinued due to an AE), 121 initiated deferred active treatment with EBR/GZR (one participant was not eligible for deferred active treatment owing to spontaneously clearing HCV infection during the placebo treatment period), and 118 completed deferred active treatment (three participants failed to complete treatment: AE, n = 2; virologic failure, n = 1) (Fig. 1) .
Participant characteristics were generally similar in the ITG and DTG (Table 1) . Approximately 80% of participants had HCV GT1b infection, 19% had cirrhosis (82% of whom were diagnosed through FibroScan ® ), and 46% had HCV RNA > 2 000 000 IU/mL at baseline (Table 1) .
Efficacy analyses
SVR12 in the immediate-treatment group/deferredtreatment group populations. In the ITG population, 94.2% (344/365; 95% CI = 91.9-96.6%) of participants who received at least one dose of EBR/GZR achieved SVR12 (Fig. 2) . Similarly, 94.4% (459/486; 95% CI 92.4-96.5%) participants from the combined ITG and DTG populations of the overall cohort achieved SVR12. Subgroup analyses revealed that SVR12 rates for the combined ITG and DTG populations were consistently high across most major subgroups, including those with cirrhosis, those with baseline viral load > 2 000 000 IU/mL, and those aged ≥ 65 years (Fig. 3) . Efficacy was also high in participants from Russia, Taiwan, China, and Republic of Korea (Fig. 3) (Table S1 ).
All virologic failures occurred before FW12. Of the 27 participants who failed to achieve SVR12, 25 had virologic failure and two discontinued due to administrative reasons. Of the 25 with virologic failure, 18 relapsed, 3 had on-treatment virologic rebound, and 4 had on-treatment breakthrough. Seventeen virologic failures had GT6 infection, the majority of whom were enrolled in Vietnam (n = 6) and Thailand (n = 7) and included all seven participants with on-treatment failure and 10 who relapsed.
SVR12 by hepatitis C virus genotype. SVR12 rates were 98.2% (382/389) in participants with GT1b infection and 91.9% (34/37) in those with GT1a infection (Fig. 4) . Conversely, participants with GT6 infection did not respond well to this treatment regimen, and only 66.7% (34/51) achieved SVR12 (Table S2 ). (Table S3 ).
SVR24.
No relapses were reported between FW12 and FW24, although one participant discontinued after FW12 because of an AE (this participant achieved SVR12 but failed to achieve SVR24). Therefore, SVR24 was achieved by 94.2% (458/486; (Table S1 ).
Resistance analyses: SVR12 analysis. In participants with HCV GT1b infection, SVR12 was high regardless of the presence of baseline NS3 or NS5A RASs (Fig. 5 ). NS3 and NS5A RASs were present at baseline in 85.4% (328/384) and 22.8% (88/386) of participants, respectively, with GT1b infection; SVR12 was achieved by 98.5% (323/328) of those with baseline NS3 RASs and 94.3% (83/88) of those with baseline NS5A RASs. SVR12 rates were slightly lower in participants with GT1a infection and baseline RASs compared with those with no baseline RASs. SVR12 was achieved by 88.0% (22/25) of those with baseline NS3 RASs compared with 100.0% (12/12) of those without baseline NS3 RASs, and 75.0% (6/8) of those with baseline NS5A RASs compared with 96.6% (28/29) of those without baseline NS5A RASs (Fig. 5 ).
All participants with GT6 infection had baseline NS3 RASs, and 44.4% (20/45) had baseline NS5A RASs (Fig. S1 ). SVR12 was achieved by 45.0% (9/20) and 80.0% (20/25) of those with and without baseline NS5A RASs. Of the 16 participants with GT6 infection and virologic failure who were available for RAS analysis, 15 had treatment-emergent NS3 RASs and seven had treatmentemergent NS5A RASs.
Of the five participants with GT1b infection with virologic failure, all five had NS5A RASs at baseline (three had Y93H, one had L31M, and one had L28M + Y93H), and all experienced relapse with Y93H and either L28M or L31M/I at the time of failure. All five participants also had NS3 RASs present at baseline and at the time of virologic failure. A full listing of all RASs present at baseline and at time of virologic failure in all participants with virologic failure is presented in Table S4 . Table 2 ). Overall and drug-related AE incidence rates during the active treatment phase in the DTG were 36.4% (44/121) and 10.7% (13/121), respectively. The most common AEs that were reported in the ITG versus the DTG placebo treatment population were upper respiratory tract infection (6.0% vs 5.7%), fatigue (5.8% vs 7.3%), and headache (5.8% vs 4.9%). No differences in the incidence of serious AEs (SAEs) (none for each) and discontinuations due to AEs (n = 1 for each population) were observed between the ITG and DTG placebo-treatment populations.
Serious adverse events were reported by 10 participants during the treatment period and the first 14 days of follow-up. In the ITG, five participants reported SAEs of suicide, contusion, Evans syndrome, lymphoma, and enteritis; in the placebo phase of the DTG, two SAEs of influenza and foot fracture were reported; and in the active treatment phase of the DTG, three participants reported SAEs of ankle fracture, atrial fibrillation, and uterine hemorrhage. Only the SAE of atrial fibrillation was considered drugrelated, and the SAE of suicide was the only death reported within the trial. Late ALT or AST elevations > 5× ULN were reported in 1.1% (4/365) of participants in the ITG and 2.5% (3/121) of participants receiving active treatment in the DTG (two of whom also reported ALT or AST levels > 500 IU/mL, necessitating treatment discontinuation). All participants with late ALT/AST elevations > 5× ULN who continued therapy experienced gradual reduction in ALT/AST while on treatment, with eventual normalization by FW4. No participants in the placebo phase of the DTG had late ALT/AST elevations > 5× ULN. ALT or AST levels > 3× ULN and > 100 IU/mL were reported by 1.6% (6/365) of participants in the ITG (1.6%) and 2.5% (3/121) of participants in the active treatment phase of the DTG. No alkaline phosphatase elevations > 3× ULN were reported. After meeting protocol-defined discontinuation criteria, treatment was discontinued by one participant in the ITG with a threefold increase in ALT from nadir value and total bilirubin > 2× ULN and two participants in the active treatment phase of the DTG with late ALT elevations > 5× ULN and ALT elevations > 500 IU/mL. All three participants who met protocol-defined discontinuation criteria achieved SVR12 and SVR24, and none experienced clinical or laboratory evidence of Data are n (%). AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphatase; BL, baseline; EBR, elbasvir; GZR, grazoprevir; IU, international unit; SAE, serious adverse event; ULN, upper limit of normal.
